Written question asked by Andrew Snowden (Conservative) on Friday, 10 October 2025, in the House of Commons. It was due for an answer on Tuesday, 14 October 2025. It was answered by Ashley Dalton (Labour) on Wednesday, 29 October 2025 on behalf of the Department of Health and Social Care.

Anaemia

Question: To ask the Secretary of State for Health and Social Care, what assessment his Department has been of the (a) long-term health outcomes and (b) quality of life of patients who have undergone treatment for aplastic anaemia.

Answer: No such assessment has been made. The majority of the treatment pathway for aplastic anaemia is an integrated care board commissioning responsibility and data is not held centrally. Hematopoietic stem cell transplant (HSCT) is a curative treatment option for aplastic anaemia. NHS England does not directly collect data on long-term outcomes and quality of life for patients with aplastic anaemia who have received a stem cell transplant. Instead, the British Society of Blood and Marrow Transplantation and Cellular Therapy collects data on transplants performed by United Kingdom transplant centres, and reports this back to the NHS England Blood and Marrow Transplantation Clinical Reference Group (CRG). This includes individual centre annual summary reports. These reports are reviewed by the CRG and insights from the analysis are shared with local commissioners so that they can address any issues with providers. However, HSCT is performed for a number of conditions and the CRG does not routinely review long-term outcomes for individual conditions at a granular level.

Secondary information